MORRISVILLE, N.C., September 7, 2022 – For any technology company to be recognized in treatment guidelines before widespread adoption is an extreme honor and a credit to the strong data and principal investigators who have diligently performed MyoStrain® studies. For the first time, the ESC issued treatment guidelines for cardio-oncology acknowledging cardiotoxicity resulting from cancer treatments as a significant problem for cancer patient health and longevity.
To become a first-line diagnostic in the guidelines, any technology must be commercially available with widespread international adoption and extensive clinical data. With extensive published evidence, MyoStrain® can become first-line by providing accurate and reproducible results to help physicians rapidly detect and manage treatment effects on the heart.
"We are excited about the possibilities of MyoStrain® in cardio-oncology in helping to solve a significant problem in cancer treatment. Cancer care has made significant advances and progress, but to fully realize these advances, the heart must be protected, accurately managed, and monitored to significantly improve patient longevity," said Dr. Rafael Rivero, chief medical officer of Myocardial Solutions Inc.
In the newly released treatment guidelines, global longitudinal strain (GLS) is supplementing ejection fraction (EF) during echocardiography (ECHO) as the first-line diagnostic test, but this may be temporary because of significant limitations.
The strong message from the ESC treatment guidelines is the need to follow cancer patients from baseline, during treatment, and throughout survivorship. The unmet medical need is to monitor patients’ cardiac risks and diseases to detect cardiac cardiotoxicity early before damage occurs. This is because dysfunction in the absence of symptoms is usually reversible.
As MyoStrain® is adopted more widely, there will be additional data demonstrating the need to quantify both regional longitudinal and circumferential strain, as well as the accuracy and reproducibility of MyoHealth™. Thus, MSI management believes the new ESC treatment guidelines help position MyoStrain® to become a first-line diagnostic test as adoption grows.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.
808 Aviation Pkwy, Suite 700 | Morrisville, NC 27560 | myocardialsolutions.com | ph: +1.919.677.8100
© Copyright 2022 Myocardial Solutions Inc. All rights reserved. MyoStrain® and the MyoHealthTM
Score are among the trademarks of Myocardial Solutions.